ONX-0801   Click here for help

GtoPdb Ligand ID: 9590

Synonyms: BGC 945 | BGC-945 | N-[4-[2-Propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-d-glutamic acid 1 [3] | ONX 0801
PDB Ligand
Compound class: Synthetic organic
Comment: ONX-0801 (originally named BGC 945) is a first-in-class small molecule inhibitor of thymidylate synthase (TS), that has been designed to accumulate differentially in cancer cells overexpressing the α-folate receptor [3] (FOLR1; P15328). Functionally, it resembles the TS inhibitors plevitrexed and raltitrexed. ONX-0801 is an oncology drug lead for epithelial tumours such as ovarian [1], lung and endometrial cancers, and mesothelioma tumours.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 14
Hydrogen bond donors 7
Rotatable bonds 17
Topological polar surface area 239.32
Molecular weight 647.22
XLogP 2.08
No. Lipinski's rules broken 3
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C#CCN(C1CCc2c1cc1c(=O)nc([nH]c1c2)CO)c1ccc(cc1)C(=O)NC(C(=O)O)CCC(=O)NC(C(=O)O)CCC(=O)O
Isomeric SMILES C#CCN([C@H]1CCc2c1cc1c(=O)nc([nH]c1c2)CO)c1ccc(cc1)C(=O)N[C@H](C(=O)O)CCC(=O)N[C@@H](C(=O)O)CCC(=O)O
InChI InChI=1S/C32H33N5O10/c1-2-13-37(25-10-5-18-14-24-21(15-20(18)25)30(43)36-26(16-38)33-24)19-6-3-17(4-7-19)29(42)35-23(32(46)47)8-11-27(39)34-22(31(44)45)9-12-28(40)41/h1,3-4,6-7,14-15,22-23,25,38H,5,8-13,16H2,(H,34,39)(H,35,42)(H,40,41)(H,44,45)(H,46,47)(H,33,36,43)/t22-,23+,25+/m1/s1
InChI Key NVHRBQOZEMFKLD-CUYJMHBOSA-N
No information available.
Summary of Clinical Use Click here for help
ONX-0801 has reached Phase 1 trial in ovarian cancer patients with advanced disease and no other treatment options (see NCT02360345). Positive results were reported in a meeting abstract (2017 ASCO Annual Meeting, abstract no 2503), which reports partial responses in an expansion cohort for all four patients whos' cancers were determined to be α-folate receptor positive (no PRs in α-folate receptor -ve tumours). These results should be onsidered preliminary pending peer-reviewed publication, and further randomized biomarker prespecified Phase 2 trials need to be conducted to confirm these findings.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
ONX-0801 combines enzymatic inhibition of thymidylate synthase with α-folate receptor-mediated targeting of tumour cells.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02360345 Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly Phase 1 Interventional Royal Marsden NHS Foundation Trust